| Factor Information | |
|---|---|
| Data ID | 3161 |
| Factor | Sertraline (SSRI) dose and exposure time during pregnacny |
| Description | Timing of the initial SSRI exposure was divided into the following categories: conception, discontinuation because of a positive pregnancy test result, first trimester, second trimester, and third trimester.Timing refers to when the mother and fetus were first exposed to the SSRI. |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | To determine the risk of congenital cardiac abnormalities associated with use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy. |
| p Value | <0.001 |
| Conclusion | The median doses of fluoxetine (P=.03) and sertraline (P<.001) differed by exposure time.Our data are reassuring regarding the safety of using SSRIs during pregnancy. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 657 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | VSD/VSD, other |
| Reference | |
|---|---|
| PMID | 19121250 |
| Year | 2009 |
| Title | Congenital Heart Disease Associated With Selective Serotonin Reuptake Inhibitor Use During Pregnancy |
| Sample | ||
|---|---|---|
| Population | adults | |
| Source | patients' data | |
| Region | Rochester, America | |
| Method | Wilcoxon ranks sum test | |
| Race | American | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | N/A(Treatment) | N/A(Control) |
| Number | 255 | N/A |
| Age | N/A | N/A |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | median=75mg (interquartile range=50-100mg) | N/A |
